Neoplasms, Plasma Cell: all 2,314 studies
Page 22 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
- Trial of Plasma Exchange for Acute Renal Failure at the Onset of MyelomaCompletedNCT00120263Not applicable
- Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple MyelomaCompletedNCT00118339Not applicable
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple MyelomaCompletedNCT00116961Phase 2
- Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple MyelomaCompletedNCT00116441Phase 1/2
- UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple MyelomaCompletedNCT00113932Phase 2
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple MyelomaCompletedNCT00113204Phase 1
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple MyelomaWithdrawnNCT00112879Phase 2
- VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple MyelomaCompletedNCT00111319Phase 3
- Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)TerminatedNCT00109109Phase 1
- Fenretinide in Treating Patients With Refractory or Relapsed Hematologic CancerCompletedNCT00104923Phase 1
- A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT00096837Phase 2
- Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
- Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00095680Phase 2
- A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)CompletedNCT00091624Phase 1
- Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell TransplantCompletedNCT00089453Phase 1
- Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic AmyloidosisCompletedNCT00089167Phase 2
- Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
- Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple MyelomaCompletedNCT00088855Phase 2
- Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00087867Phase 2
- Safety and Efficacy of Atiprimod for Patients With Refractory Multiple MyelomaCompletedNCT00086216Phase 1/2
- Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00085449Phase 1/2
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT00085345Phase 2
- Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage TherapyCompletedNCT00083902Phase 2
- D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple MyelomaCompletedNCT00083876Phase 3
- DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation RelapseCompletedNCT00083681Phase 2
- Anti-Angiogenesis Therapy Using Thalidomide in Multiple MyelomaCompletedNCT00083577Phase 2
- Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple MyelomaTerminatedNCT00083564Phase 3
- Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or IntranodallyCompletedNCT00083538Phase 2
- Study of Combination PS-341 and Thalidomide in Multiple MyelomaCompletedNCT00083460Phase 1
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083408Phase 2
- Study of the Emotional Needs of Caregivers of Stem Cell Transplantation PatientsCompletedNCT00082654Not applicable
- T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
- Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple MyelomaCompletedNCT00080405Phase 1
- Study of SGN-40 in Patients With Refractory or Recurrent Multiple MyelomaCompletedNCT00079716Phase 1
- Temsirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00079456Phase 2
- Xcellerated T CellsTM in Patients With Multiple MyelomaCompletedNCT00078065Phase 2
- Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
- Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesCompletedNCT00068523Not applicable
- Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT00067639Phase 2
- FR901228 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00066638Phase 2
- Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
- Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT00065351Phase 2
- Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
- A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADENo longer availableNCT00063791
- A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039CompletedNCT00063726Phase 3
- Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney FailureCompletedNCT00062621Phase 1
- Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With CancerTerminatedNCT00062231Not applicable
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00060255Phase 2
- Brostallicin in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00060203Phase 1/2
- Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGELCompletedNCT00058617Phase 1
- Epoetin Alfa in Treating Anemia in Patients With Solid TumorsCompletedNCT00058331Phase 3
- A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple MyelomaCompletedNCT00057564Phase 3
- Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
- Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 1
- Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00054158Phase 2
- Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic CancerCompletedNCT00053196Phase 2
- Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell TransplantationTerminatedNCT00052884Phase 1
- A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple MyelomaCompletedNCT00051116Phase 2
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00049374Phase 2
- Cytogenetic Studies in Acute Leukemia and Multiple MyelomaActive, not recruitingNCT00048958
- T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow TransplantStatus unknownNCT00048464Phase 1/2
- Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1HCompletedNCT00048412Phase 1/2
- PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00048230Phase 3
- Efficacy Study of ZD6474 to Treat Multiple Myeloma CancerCompletedNCT00047788Phase 2
- Flavopiridol in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00047203Phase 2
- Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple MyelomaCompletedNCT00046852Phase 1/2
- Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaCompletedNCT00045136Phase 1/2
- Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00044954Phase 2
- CDC-501 Therapy in Relapsed or Refractory Multiple MyelomaCompletedNCT00044018Phase 2
- Pyroxamide in Treating Patients With Advanced CancerCompletedNCT00042900Phase 1
- A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple MyelomaTerminatedNCT00039754Phase 1/2
- Thalidomide for Multiple MyelomaCompletedNCT00038233Phase 3
- Thalidomide-Dexamethasone for Multiple MyelomaCompletedNCT00038090Phase 2/3
- Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced CancerCompletedNCT00036790Phase 1
- Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow TransplantationStatus unknownNCT00036712Phase 2
- Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple MyelomaCompletedNCT00036140Phase 1
- Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00033332Phase 3
- Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple MyelomaStatus unknownNCT00028886Phase 3
- 2-Methoxyestradiol in Treating Patients With Advanced Solid TumorsCompletedNCT00028821Phase 1
- Peripheral Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00028600Phase 2
- Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00024466Phase 1/2
- SU006668 in Treating Patients With Advanced Solid TumorsStatus unknownNCT00024063Phase 1
- Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00022607Phase 2
- AE-941 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00022282Phase 2
- Isotretinoin Plus Dexamethasone in Treating Patients With Multiple MyelomaCompletedNCT00021359Phase 2
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 2
- Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00017602Phase 3
- Arsenic Trioxide in Treating Patients With Multiple MyelomaTerminatedNCT00017433Phase 2
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple MyelomaTerminatedNCT00017069Phase 2
- MS-275 in Treating Patients With Hematologic CancerCompletedNCT00015925Phase 1
- Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaCompletedNCT00014508Phase 2
- Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell TransplantationCompletedNCT00014482Not applicable
- Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple MyelomaStatus unknownNCT00014339Phase 3
- Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
- Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple MyelomaCompletedNCT00012350Phase 2